Journal article
The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial
Anton Camaj, Bimmer E Claessen, Roxana Mehran, Matias B Yudi, David Power, Usman Baber, Christian Hengstenberg, Thierry Lefevre, Eric Van Belle, Gennaro Giustino, Paul Guedeney, Sabato Sorrentino, Christian Kupatt, John G Webb, David Hildick-Smith, Hans U Hink, Efthymios N Deliargyris, Prodromos Anthopoulos, Samin K Sharma, Annapoorna Kini Show all
Catheterization and Cardiovascular Interventions | WILEY | Published : 2020
DOI: 10.1002/ccd.28717
Abstract
BACKGROUND/OBJECTIVES: Clinicians use validated scores to risk-stratify patients undergoing transcatheter aortic valve replacement (TAVR). However, evaluation by the Heart Team often deems patients to be at higher risk than their formal scores suggest. We sought to assess clinical outcomes of TAVR patients defined as high-risk by the Heart Team's assessment versus the patient's logistic EuroSCORE (LES). METHODS: The BRAVO-3 trial randomized patients at high risk (LES ≥ 18, or deemed inoperable by the Heart Team) to TAVR with periprocedural anticoagulation with unfractionated heparin versus bivalirudin. Endpoints included net adverse cardiac events (NACE: the composite of all-cause mortality,..
View full abstractGrants
Funding Acknowledgements
The Medicines Company